

Bench to Boardroom: A Conversation with Pradeep Natarajan
MCBcDNA is pleased to welcome Dr. Pradeep Natarajan, Vice President of Global Research, Head of Cardiometabolic Research, and Human Genetics at Amgen—and former MCBcDNA president!—for a fireside chat. Join us to hear his perspective on the intersection of human genetics, drug discovery, and the future of cardiovascular and metabolic medicine.
Dr. Natarajan is a physician-scientist whose work bridges human genetics, cardiovascular medicine, and therapeutic discovery. At Amgen, he leads research efforts focused on leveraging human genetics to uncover disease mechanisms, identify novel therapeutic targets, and accelerate the development of new medicines. Prior to joining Amgen, he served as Director of Preventive Cardiology at Massachusetts General Hospital, Paul and Phyllis Fireman Endowed Chair in Vascular Medicine, and Associate Professor of Medicine at Harvard Medical School. He also held an appointment at the Broad Institute of Harvard and MIT. He earned his BA in Molecular and Cell Biology from the University of California, Berkeley, his MD from UCSF, and his Master of Medical Sciences in Biomedical Informatics from Harvard Medical School. His pioneering research has demonstrated how naturally occurring genetic variation can reveal disease biology and validate potential drug targets. His work in cardiovascular genetics is particularly relevant to the development of PCSK9-targeting therapies, including Amgen's Repatha, illustrating the power of translating genetic discoveries into transformative medicines. He has authored more than 400 scientific publications and received numerous honors, including the American Heart Association's 2023 Joseph A. Vita Award.
In this conversation, we'll discuss Dr. Natarajan's transition from academic medicine to scientific leadership at Amgen, how human genetics is transforming drug discovery, and what it takes to translate fundamental biological insights into new therapies. We'll explore the role of large-scale genetic studies and deCODE Genetics in identifying therapeutic targets, the lessons from PCSK9 and Repatha, and emerging opportunities in cardiovascular and metabolic disease, including obesity. Finally, we'll hear his perspective on the future of pharmaceutical research and building a career at the intersection of science, medicine, and biotechnology.
Agenda
7:30 PM — Event starts
7:40–7:45 PM — Welcome & introductions
7:45–8:15 PM — Fireside Chat with Pradeep Natarajan
8:15–8:30 PM — Audience Q&A
8:30–9:00 PM — Networking reception with food & drinks
Event Sponsor: Quartzy
Quartzy is a lab management and procurement platform used by research labs worldwide, helping scientists order supplies, track inventory, and manage purchasing in one place so they can spend less time on logistics and more time on science. Learn more at quartzy.com.
Series Partner: Biocom California
Biocom California is the largest life science association in the state, and through its Biocom Institute it works to connect students and emerging talent with careers across biotech and the life sciences. Learn more at biocom.org.